RELMADA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
RELMADA THERAPEUTICS, INC. (RLMD) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 5.23% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-19
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 5.23%.
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.00%, a 100.00% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 1.64%, a 7.19% increase from fiscal 2021.
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was 1.53%, a 52.34% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 6 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|---|
| 2024-12-31 | 5.23% 10-K · filed 2026-03-19 | ||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-27 | 1.70% 10-K · filed 2024-03-19 | |
| 2022-12-31 | 1.64% 10-K · filed 2024-03-19 | ||
| 2021-12-31 | 1.53% 10-K · filed 2023-03-23 | ||
| 2020-12-31 | 3.21% 10-K · filed 2022-03-25 | ||
| 2019-12-31 | 0.00% 10-KT · filed 2020-03-26 | 3.02% 10-K · filed 2021-03-24 | |
| 2019-06-30 | 0.00% 10-KT · filed 2020-03-26 | ||
| 2018-12-31 | 0.00% 10-KT · filed 2020-03-26 | ||
| 2018-06-30 | -71.60% 10-KT · filed 2020-03-26 | ||
| 2015-06-30 | 0.60% 10-K · filed 2016-09-09 | ||
| 2014-12-31 | -2.30% 10-K · filed 2015-09-11 | ||
| 2014-06-30 | -2.30% 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |